

Substitute for form 1449B/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

LISTING OF REFERENCES

November 9, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3593.1001-008

APPLICATION NO.
10/526,185

FIRST NAMED INVENTOR
Gordon D. Ross (deceased)

371(c) DATE
August 3, 2005

EXAMINER
Pagonakis, Anna

CONFIRMATION NO.
6460

GROUP
4173

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1	3,903,297	09-02-1975	Robert
	A2	4,237,266	12-02-1980	Sugiura <i>et al.</i>
	A3	4,492,540	01-08-1985	Yamamoto
	A4	4,810,646	03-07-1989	Jamas <i>et al.</i>
	A5	4,992,540	02-12-1991	Jamas <i>et al.</i>
	A6	5,037,972	08-06-1991	Jamas <i>et al.</i>
	A7	5,082,936	01-21-1992	Jamas <i>et al.</i>
	A8	5,223,409	06-29-1993	Ladner <i>et al.</i>
	A9	5,223,491	06-29-1993	Donzis
	A10	5,250,436	10-05-1993	Jamas <i>et al.</i>
	A11	5,506,124	04-09-1996	Jamas <i>et al.</i>
	A12	5,576,015	11-19-1996	Donzis
	A13	5,702,719	12-30-1997	Donzis
	A14	5,766,571	06-16-1998	Ceriani <i>et al.</i>
	A15	4,810,646	03-07-1989	Jamas <i>et al.</i>
	A16	4,761,402	08-02-1988	Williams <i>et al.</i>
	A17	4,739,046	04-19-1988	DiLuzio <i>et al.</i>
	A18	4,138,479	02-06-1979	Truscheit <i>et al.</i>
	A19	4,707,471	11-17-1987	Larm <i>et al.</i>

EXAMINER

DATE CONSIDERED

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008	APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)	371(c) DATE August 3, 2005	
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6460	GROUP 4173

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A20	5,032,401	07-16-1991	Jamas <i>et al.</i>
	A21	5,057,503	10-15-1991	Czop <i>et al.</i>
	A22	5,322,841	11-02-1992	Jamas <i>et al.</i>
	A23	5,320,849	06-14-1994	Hagiwara <i>et al.</i>
	A24	5,488,040	01-30-1996	Jamas <i>et al.</i>
	A25	5,532,223	07-02-1996	Jamas <i>et al.</i>
	A26	5,622,939	04-22-1997	Jamas <i>et al.</i>
	A27	3,943,247	03-09-1976	Komatsu <i>et al.</i>
	A28	5,504,079	04-02-1996	Jamas <i>et al.</i>
	A29	5,401,647	03-28-1995	Tanaka <i>et al.</i>
	A30	5,783,569	07-21-1998	Jamas <i>et al.</i>
	A31	5,817,643	10-06-1998	Jamas <i>et al.</i>
	A32	4,975,421	12-04-1990	Williams <i>et al.</i>
	A33	5,474,984	12-12-1995	Tanaka <i>et al.</i>
	A34	4,946,450	08-07-1990	Erwin
	A35	5,663,324	09-02-1997	Jamas <i>et al.</i>
	A36	5,633,369	05-27-1997	Jamas <i>et al.</i>
	A37	5,811,542	09-22-1998	Jamas <i>et al.</i>
	A38	5,849,720	12-15-1998	Jamas <i>et al.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		371(c) DATE August 3, 2005	
	EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6460	

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A39	5,607,677	03-04-1997	Jamas <i>et al.</i>
	A40	5,741,495	04-21-1998	Jamas <i>et al.</i>
	A41	4,818,752	04-04-1989	Williams <i>et al.</i>
	A42	US 2004/0116380	06-17-2004	Jamas <i>et al.</i>
	A43	6,235,272	05-22-2001	Greene
	A44	5,705,184	01-06-1998	Donzis <i>et al.</i>
	A45	5,397,773	03-14-1995	Donzis <i>et al.</i>
	A46	5,028,703	07-02-1991	Jamas <i>et al.</i>
	A47	US 2006/0165700	07-27-2006	Ostroff <i>et al.</i>
	A48	US 2005/0245480	11-03-2005	Ostroff <i>et al.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		371(c) DATE August 3, 2005	
	EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6460	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B2	WO 2004/021994 A2	03-18-2004	Biopolymer Engineering, Inc. <i>et al.</i>		
	B3	WO 2004/030613 A2	04-15-2004	University of Louisville Research Foundation, Inc.		
	B4	WO 2006/085895 A2	08-17-2006	Biopolymer Engineering, Inc. <i>et al.</i>		
	B5	CN 1082056 A (English Abstract Only)	02-16-1994	Consiglio Nazionale delle Ricerche <i>et al.</i>		X
	B6	WO 94/03500 A1	02-17-1994	Consiglio Nazionale delle Ricerche <i>et al.</i>		

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		371(c) DATE August 3, 2005	
	EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6460	GROUP 4173

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C3	Cheung, N.V. <i>et al.</i> , "Oral (1→3), (1→4)-β-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 8(5): 1217-1223 (May 2002).
C4	Yan, J. <i>et al.</i> , "β-Glucan, a 'Specific' Biologic Response Modifier that uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)," <i>Journal of Immunology</i> , Vol. 163(6): 3045-3052 (September 1999).
C5	Ross, Gordon D. <i>et al.</i> , "Therapeutic Intervention with Complement and β-Glucan in Cancer," <i>Immunopharmacology</i> , 42: 61-74 (1999).
C6	DATABASE MEDLINE in STN. (Columbus, OH, USA) AN 2000285552, Yadomae, T., "Structure and Biological Activities of Fungal beta-1,3-glucans," <i>J. Pharmaceutical Soc. Jap.</i> , 120(5): 413-431 (2000), Abstract Only.
C7	Bohn, J.A. <i>et al.</i> , "(1→3)-β-D-Glucans as Biological Response Modifiers: A Review of Structure-Functional Activity Relationships," <i>Carbohydrate Polymers</i> , 28: 3-14 (1995).
C8	Database HCAPLUS on STN (Columbus, OH, USA), No. 137:119657, Cheung, N., "Antitumor Antibody-Enhancing Glucan," WO2002058711A1, 01 August 2002, abstract, see entire abstract.
C9	Database DRUGU on STN (Columbus, OH, USA), AN 1998:11655, Coiffier, B. <i>et al.</i> , "A Multicenter, Randomized Phase II Study of Rituximab (Chimeric Anti-CD20 mAb) at Two Dosages in Patients with Relapsed or Refractory Intermediate or High-Grade NHL (IHG-NHL) or in Elderly Patients in First-Line Therapy," <i>Blood</i> (90, No. 10, Suppl. 1 Pt 1): 510A, 1997, Abstract, see entire Abstract.
C10	Database DRUGU on STN (Columbus, OH, USA), AN 1990-03601, Srivastava, R. <i>et al.</i> , "Bioactive Polysaccharides from Plants," <i>Phytochemistry</i> , Vol. 28, No. 11, pages 2877-2883, 1989, Abstract, see entire Abstract.
C11	Borchers, A.T. <i>et al.</i> , "MINIREVIEW: Mushrooms, Tumors, and Immunity," <i>Mushrooms and Immunity</i> , 221(4): 281-293 (1999).
C12	Sveinbjörnsson, <i>et al.</i> , "Macrophage Cytotoxicity Against Murine Meth A Sarcoma Involves Nitric Oxide-Mediated Apoptosis," <i>Biochem. Biophys. Res. Commun.</i> , 223(3): 643-649 (1996).
C13	Xia, Y. <i>et al.</i> , "The β-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells," <i>J. Immunol.</i> , 162: 2281-2290 (1999).
C14	Thornton, B.P. <i>et al.</i> , "Analysis of the Sugar Specificity and Molecular Location of the γ-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/CD18)," <i>J. Immunol.</i> , 156: 1235-1246 (1996).
C15	Ross, G.D. <i>et al.</i> , "Membrane Complement Receptor Type Three (CR3) has Lectin-Like Properties Analogous to Bovine Conglutinin and Functions as a Receptor for Zymosan and Rabbit Erythrocytes as well as a Receptor for iC3b," <i>The Journal of Immunology</i> , 134(5): 3307-3315

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185	
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		371(c) DATE August 3, 2005	
	EXAMINER Pagonakis, Anna		CONFIRMATION NO. 6460	GROUP 4173

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	(1985).
C16	Ross, G.D. <i>et al.</i> , "Specificity of Membrane Complement Receptor Type Three (CR3) for β -Glucans," <i>Complement</i> , 4: 61-74 (1987).
C17	Cain, J.A., <i>et al.</i> , "Role of Complement Receptor Type Three and Serum Opsonins in the Neutrophil Response to Yeast," <i>Complement</i> , 4: 75-86 (1987).
C18	Suzuki, I. <i>et al.</i> , "Inhibition of Experimental Pulmonary Metastasis of Lewis Carcinoma by Orally Administered β -Glucan in Mice," <i>Chem. Pharm. Bull.</i> , 39(6): 1606-1608 (1991).
C19	Roubey <i>et al.</i> , "Staurosporine Inhibits Neutrophil Phagocytosis but not iC3b Binding Mediated by CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 146(10): 3557-3562 (1991).
C20	Ross, G.D. <i>et al.</i> , "CR3 (CD11b, CD18): A Phagocyte and NK Cell Membrane Receptor with Multiple Ligand Specificities and Functions," <i>Clin Exp Immunol</i> , 92: 181-184 (1993).
C21	Muto, Satoshi <i>et al.</i> , "CR3 (CD11b/CD18) Expressed by Cytotoxic T Cells and Natural Killer Cells is Upregulated in a Manner Similar to Neutrophil CR3 Following Stimulation with Various Activating Agents," <i>Journal of Clinical Immunology</i> , 13(3): 175-184 (1993).
C22	Vetvicka, V. <i>et al.</i> , "Soluble β -Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type 3 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells," <i>J. Clin. Invest.</i> , 98(1): 50-61 (1996).
C23	Vetvicka, V. <i>et al.</i> , "Targeting of Natural Killer Cells to Mammary Carcinoma via Naturally Occurring Tumor Cell-Bound iC3b and beta-glucan-primed CR3 (CD11b/CD18)," <i>J. Immunol</i> , 159(2): 599-605 (1997).
C24	Reddy, R.K. <i>et al.</i> , "A Mixed Population of Immature and Mature Leucocytes in Umbilical Cord Blood Results in a Reduced Expression and Function of CR3 (CD11b/CD18)," <i>Clin Exp Immunol</i> , 114: 462-467 (1998).
C25	Xia, Y. <i>et al.</i> , "Generation of Recombinant Fragments of CD11b Expressing the Functional γ -Glucan-Binding Lectin Site of CR3 (CD11b/CD18)," <i>The Journal of Immunology</i> , 162(12): 7285-7293 (1999).
C26	Vetvicka, V. <i>et al.</i> , "Regulation of CR3 (CD11b/CD18)-dependent Natural Killer (NK) Cell Cytotoxicity by Tumour Target Cell MHC Class I Molecules," <i>Clin Exp Immunol</i> , 115: 229-235 (1999).
C27	Yan, J. <i>et al.</i> , "Critical Role of Kupffer Cell CR3 (CD11b/CD18) in the Clearance of IgM-Opsonized Erythrocytes or Soluble β -Glucan," <i>Immunopharmacology</i> , 46: 39-54 (2000).
C28	Ross, G.D., "Regulation of the Adhesion Versus Cytotoxic Functions of the Mac-1/CR3/ γ_5 Integrin Glycoprotein," <i>Critical Reviews in Immunology</i> , 20: 197-222 (2000).
C29	Ross, G.D., "Role of the Lectin Domain of Mac-1/CR3 (CD11b/CD18) in Regulating Intercellular Adhesion," <i>Immunologic Research</i> , 25(3): 219-227 (2002).
C30	Biopolymer Engineering Presentation: Pioneering Carbohydrate Technology to Improve Human Health, April 2003.
C31	Blakeslee, Dennis, "The Two Faces of Immunity: Th1 and Th2," JAMA HIV/AIDS Resource Center, The Journal of the American Medical Association, http://www.ama-assn.org/special/hiv/newsline/briefing/th1.htm (8/12/2002).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES November 9, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3593.1001-008		APPLICATION NO. 10/526,185
	FIRST NAMED INVENTOR Gordon D. Ross (deceased)		371(c) DATE August 3, 2005
	EXAMINER Pagonakis, Anna	CONFIRMATION NO. 6460	GROUP 4173

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
C32	"What's the Difference of Th1 Cells and Th2 Cells Effect?" http://www.madsci.org/posts/archives/may99/926272023.lm.r.html (May 8, 1999).
C33	Heron Herbals: Feature Articles: "Balancing Cellular and Humoral Immunity," http://www.healthcalls.net/hh_art1alt.html (8/16/2002).
C34	Kournikakis <i>et al.</i> , "Anthrax-Protective Effects of Yeast Beta 1,3 Glucans," <i>Medscape General Medicine</i> , 03/21/2003, 4 sheets.
C35	Vetvicka, V. <i>et al.</i> , "Pilot Study: Orally Administered Yeast Beta 1,3-Glucan Prophylactically Protects Against Anthrax Infection and Cancer in Mice," <i>J. Amer. Nutr. Assoc.</i> , 5(2): 1-5 (2002).
C36	Nanba <i>et al.</i> , "Antitumor Action of Shiitake (<i>Lentinus edodes</i>) Fruit Bodies Orally Administered to Mice," <i>Chem. Pharm. Bull. (Tokyo)</i> , 35(6): 2453-2458 (1987).
C37	Toi <i>et al.</i> , "Randomized Adjuvant Trial to Evaluate the Addition of Tamoxifen and PSK to Chemotherapy in Patients with Primary Breast Cancer," <i>Cancer</i> , 70(10): 2475-2483 (1992).
C38	Onderdonk, A. <i>et al.</i> , "Anti-Infection Effect of Poly-Beta 1-6-Glucopyranosyl-Beta 1-3-Glucopyranose Glucan in vivo," <i>Infect. Immun.</i> , 60(4): 1642-1647 (1992).
C39	Kaiser, A.B. <i>et al.</i> , "Synergism Between Poly-(1-6)-Beta-D-Glucopyranosyl-(1,3)-Beta-D-Glucopyranose Glucan and Cefazolin in Prophylaxis of Staphylococcal Wound Infection in a Guinea Pig Model," <i>Antimicrob. Agents Chemother.</i> , 42(9): 2449-2451 (1998).
C40	Hassid <i>et al.</i> , "The Molecular Constitution of an Insoluble Polysaccharide from Yeast, <i>Saccharomyces cerevisiae</i> ," <i>Journal of the American Chemical Society</i> , 63: 295 (1941).
C41	Wessels, M.R. <i>et al.</i> , "Studies of Group B Streptococcal Infection in Mice Deficient in Complement Component C3 or C4 Demonstrate an Essential Role for Complement in Both Innate and Acquired Immunity," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 11490-11494 (1995).
C42	Yan, J. <i>et al.</i> , "β-Glucan, a 'Specific' Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)1," <i>The Journal of Immunology</i> , 163: 3045-3052 (1999).

EXAMINER	DATE CONSIDERED
----------	-----------------